Insel Gruppe AG, University Hospital Bern — Biomedical Watch V2

Traitements4programmes

Essais4liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?The investigators hypothesize that hypogammaglobulinemia (defined as IgG serum concentration \<7.0g/L) is a treatable cause of fatigue in people with MS: The primary objective is to prove the link between hypogammaglobulinemia and fatigue in patients with multiple sclerosis. The secondary objective is to show that fatigue is mediated via frequent infections in people with MS and hypogammaglobulinemia.	SEP	À vérifier	Traitement symptomatique	Switzerland	À vérifier
OPAMA — Oxygenation and Perfusion in Patients With Acute Migraine AttacksThe aim of the study is to retrospectively evaluate brain perfusion and oxygenation in acute migraine attacks. Magnetic resonance perfusion and susceptibility weighted imaging are the technics to measure perfusion and oxygenation respectively.	Migraine	À vérifier	À vérifier		À vérifier
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?The investigators hypothesize that hypogammaglobulinemia (defined as IgG serum concentration \<7.0g/L) is a treatable cause of fatigue in people with MS: The primary objective is to prove the link between hypogammaglobulinemia and fatigue in patients with multiple sclerosis. The secondary objective is to show that fatigue is mediated via frequent infections in people with MS and hypogammaglobulinemia.	SEP	À vérifier	Traitement symptomatique	Switzerland	À vérifier
OPAMA — Oxygenation and Perfusion in Patients With Acute Migraine AttacksThe aim of the study is to retrospectively evaluate brain perfusion and oxygenation in acute migraine attacks. Magnetic resonance perfusion and susceptibility weighted imaging are the technics to measure perfusion and oxygenation respectively.	Migraine	À vérifier	À vérifier		À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution	Migraine	Phase 4	NCT07653516	Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness	NOT_YET_RECRUITING
OPAMA — Oxygenation and Perfusion in Patients With Acute Migraine Attacks	Migraine	À vérifier	NCT03536936	OPAMA — Oxygenation and Perfusion in Patients With Acute Migraine Attacks	COMPLETED
Fremanezumab	Migraine	À vérifier	NCT06659120	FROMM — Fremanezumab for the Prevention of Menstrually-related Migraine Attacks	RECRUITING
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?	SEP	À vérifier	NCT05357781	Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.